Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.
ACS Medicinal Chemistry Letters June 12, 2025 DOI: 10.1021/acsmedchemlett.5c00263 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Drug development Drug discovery Pharmaceutical research Novel compounds Therapeutic innovation Neuropsychiatry Brain disorders Mental health Metabolic health Metabolic disorders Non-hallucinogenic therapies Non-psychedelic treatments |
| Key findings | Substituted tryptamines with selective 5-HT2A/2C activity offer therapeutic promise for metabolic and neuropsychiatric disorders without psychedelic effects. |
Abstract
Substituted tryptamines with selective 5-HT2A/2C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment strategies.
Citations in the library
Cites 5
- Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges Brain Sciences February 6, 2025
- The Emergence of Psilocybin in Psychiatry and Neuroscience Pharmaceuticals April 9, 2025
- Utilizing Psychedelics to Enhance Well-Being: A Systematic Review Journal of Psychoactive Drugs March 31, 2025
- From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice Pharmacology Research & Perspectives April 1, 2025
- Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes Neuropharmacology March 7, 2025